- Home
- THTX vs GNLX Comparison
THTX vs GNLX Comparison
Compare THTX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- GNLX
- Stock Information
- Founded
- THTX 1993
- GNLX 2001
- Country
- THTX Canada
- GNLX United States
- Employees
- THTX N/A
- GNLX N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- THTX Health Care
- GNLX Health Care
- Exchange
- THTX Nasdaq
- GNLX Nasdaq
- Market Cap
- THTX 119.1M
- GNLX 129.9M
- IPO Year
- THTX N/A
- GNLX 2023
- Fundamental
- Price
- THTX $3.14
- GNLX $3.30
- Analyst Decision
- THTX Hold
- GNLX Strong Buy
- Analyst Count
- THTX 1
- GNLX 4
- Target Price
- THTX N/A
- GNLX $17.75
- AVG Volume (30 Days)
- THTX 1.1M
- GNLX 125.7K
- Earning Date
- THTX 07-09-2025
- GNLX 08-13-2025
- Dividend Yield
- THTX N/A
- GNLX N/A
- EPS Growth
- THTX N/A
- GNLX N/A
- EPS
- THTX N/A
- GNLX N/A
- Revenue
- THTX $84,378,000.00
- GNLX N/A
- Revenue This Year
- THTX N/A
- GNLX N/A
- Revenue Next Year
- THTX $15.13
- GNLX N/A
- P/E Ratio
- THTX N/A
- GNLX N/A
- Revenue Growth
- THTX 2.19
- GNLX N/A
- 52 Week Low
- THTX $1.12
- GNLX $1.60
- 52 Week High
- THTX $3.20
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- THTX 71.86
- GNLX 59.72
- Support Level
- THTX $2.28
- GNLX $3.00
- Resistance Level
- THTX $3.20
- GNLX $3.50
- Average True Range (ATR)
- THTX 0.04
- GNLX 0.23
- MACD
- THTX 0.03
- GNLX 0.01
- Stochastic Oscillator
- THTX 93.48
- GNLX 71.60
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.